65 First-generation (eg, gefitinib and erlotinib) and second-generation (eg, afatinib and dacomitinib) EGFR TKIs have significantly improved PFS, and overall survival in the case of dacomitinib, ...

The Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety data that raises the chances of approval when pivotal trials read ...

在1/1.5 mg/kg剂量组，IBI363取得了优异的ORR、DCR、PFS、OS数据，中位OS达15.3个月，提示IBI363通过“PD-1靶向+IL-2激活扩增肿瘤特异性T细胞”的免疫检查点 ...

At 1 year, two-thirds of patients treated with inclisiran (Leqvio; Novartis) on top of statin and nonstatin lipid-lowering therapies achieved an LDL target of less than 70 mg/dL compared with just ...

Relacorilant in addition to nab-paclitaxel demonstrated a significant improvement in progression-free survival (PFS) and prolonged overall survival (OS) vs nab ...

Inclisiran is a new and potent lipid-lowering drug that is shown to be effective in reducing LDL-c in randomised controlled trials, however, real-world data of its use are not yet known. We sought to ...

The median progression-free survival was 20.6 months in the dostarlimab-niraparib-chemotherapy arm and 19.2 months in the niraparib-chemotherapy arm. Adding dostarlimab to platinum-based ...

The FIRST/ENGOT-OV44 trial found dostarlimab plus platinum-chemo and niraparib maintenance modestly improved PFS (20.6 vs 19.2 months) in advanced ovarian cancer, with expected safety. Frontline ...

研究的主要终点为独立评审委员会（IRC）评估的无进展生存期（PFS）；次要终点包括总生存期（OS）、客观缓解率（ORR）及安全性指标等。 研究结果： 从2021年8月至2022年12月，共531例患者完成随机分组（528例接受治疗）。截至2023年5月20日的数据截止时间点 ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

Median PFS was not reached for D-VRd, indicating prolonged disease control, while VRd had a median PFS of 49.6 months. The study supports D-VRd as a new standard of care for transplant-ineligible ...